Posts by: Patricia Inacio PhD

Patricia Inacio PhD

Patricia holds her Ph.D. in Cell Biology from University Nova de Lisboa, and has served as an author on several research projects and fellowships, as well as major grant applications for European Agencies. She also served as a PhD student research assistant in the Laboratory of Doctor David A. Fidock, Department of Microbiology & Immunology, Columbia University, New York.

December 5, 2019December 9, 2019

China OKs Lynparza as Maintenance Therapy for Advanced Ovarian Cancers with BRCA Mutations

News

Oral Lynparza (olaparib) has been approved in China as a first-line maintenance treatment for women with BRCA-mutated advanced ovarian cancer who responded to initial platinum-based chemotherapy, AstraZeneca and Merck (known as MSD ... Read more

September 16, 2019

Collaborators Aim to Identify OC Patients Likely to Benefit from New Combo Therapy

News

The University of New Mexico (UNM) Comprehensive Cancer Center and the New Mexico Alliance for Cancer Care have entered a collaboration with Personalis to use its cancer immunogenomics platform to ... Read more

September 13, 2019

TCR2 Therapeutics, National Cancer Institute Team Up to Develop TC-210 Immunotherapy

News

TCR2 Therapeutics has partnered with Raffit Hassan, MD, at the National Cancer Institute to test TC-210, a mesothelin-specific immunotherapy, in an ongoing Phase 1/2 clinical trial for people with advanced ... Read more

July 8, 2019

Lynparza Approved in Japan as First-Line Maintenance Therapy for Advanced OC

News

Lynparza (olaparib) has been approved in Japan as a first-line maintenance treatment for women with BRCA-mutated advanced ovarian cancer that is responding, partially or completely, to their initial chemotherapy, AstraZeneca and Merck (known ... Read more

May 29, 2019May 29, 2019

Grant Lets Researchers Study OC Patients’ Responses to PARP Inhibitors

News

Researchers at Michigan State University (MSU) were granted $50,000 to investigate why only a fraction of ovarian cancer patients respond to treatment with PARP inhibitors. The grant, awarded by the ... Read more

May 8, 2019

Lynparza Recommended for Approval in Europe for BRCA-mutated Advanced OC

News

The Committee for Medicinal Products for Human Use (CHMP), an arm of the European Medicines Agency (EMA), has recommended that Lynparza (olaparib) be approved as a first-line maintenance therapy for women with ... Read more

April 24, 2019

Surgeons Will Test LUM Imaging System to Better Detect Ovarian, Other Cancer Cells

News

Lumicell is assessing its LUM Imaging System as a means to help surgeons better detect cancer cells that spread into the peritoneum — the membrane lining the abdominal cavity and ... Read more

March 29, 2019

Phase 3 Trial Launched to Test TTFields-Taxol Combo on Platinum-resistant Ovarian Cancer

News

Novocure has initiated a Phase 3 trial investigating its Tumor Treating Fields (TTFields) — a method that uses electric fields to disrupt cell division — in combination with Taxol (paclitaxel) ... Read more

March 27, 2019

Patients with Platinum-sensitive Ovarian Cancer Live Longer on SOTIO’s Immunotherapy, Trial Shows

News

Adding SOTIO’s ovarian cancer immunotherapy DCVAC/OvCa to standard second-line chemotherapy significantly extends the lives of women with advanced ovarian cancer who initially responded to their first-line chemotherapy, a Phase 2 ... Read more

March 22, 2019

Low White Blood Cell Count May Help Predict Some Ovarian Cancer Outcomes

News

A reduced number of lymphocytes — one of the main types of immune cells — in advanced ovarian cancer patients before treatment is linked with a higher risk of disease ... Read more